Cynaropicrin Potentiates the Anti-Tumor Effects of Paclitaxel and 5-Fluorouracil on KYSE30 Human Esophageal Carcinoma

Solmaz Nasirzadeh

Ferdowsi University of Mashhad

Ahmad Reza Bahrami

Ferdowsi University of Mashhad

Seyed Navid Goftari

Ferdowsi University of Mashhad

Abolfazl Shakeri

Mashhad University of Medical Sciences

Mehrdad Iranshahi

Mashhad University of Medical Sciences

Maryam M. Matin (✉ Matin@um.ac.ir)

Ferdowsi University of Mashhad <https://orcid.org/0000-0002-7949-7712>

Research Article

Keywords: Esophageal cancer, Combination therapy, Cynaropicrin, Synergistic effects.

Posted Date: August 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-816266/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Cynaropicrin potentiates the anti-tumor effects of paclitaxel and 5-fluorouracil on KYSE30 human esophageal carcinoma

Solmaz Nasirzadeh¹, Ahmad Reza Bahrami^{1,2}, Seyed Navid Goftari¹, Abolfazl Shakeri³, Mehrdad Iranshahi^{3,4}, Maryam M. Matin^{1,5*}

1. Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran

2. Industrial Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

3. Department of Pharmacognosy, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4. Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

5. Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

E-mail: matin@um.ac.ir

Tel: +98-51-38805514

Fax: +98-51-38796416

Abstract

Natural products or their use in combination therapy regimens may reduce side effects of chemotherapy and increase the effectiveness of treatments. The cytotoxic effects of cynaropicrin, a sesquiterpene lactone isolated from *Centaurea behen* were evaluated for the first time against esophageal squamous carcinoma cells (KYSE30). The synergistic effects of cynaropicrin with paclitaxel and 5-fluorouracil (5-Fu), conventional chemotherapeutic drugs used for esophageal cancer treatment, were also investigated. MTT results indicated that the 50% inhibitory concentration (IC₅₀) values of cynaropicrin on KYSE30 cells after 24, 48 and 72 h were 72, 43 and 28 μ M, respectively, which were significantly different from those on normal HDF cells. It was also determined that cynaropicrin could induce the cell death via apoptosis. Our results indicated that cynaropicrin had synergism with both drugs. The best effects of cynaropicrin in combination with paclitaxel were observed at 48 h, in which dose reduction of paclitaxel reached 3 times in IC₅₀. Combination with 5-fluorouracil, resulted in 15 times dose reduction of 5-Fu in IC₅₀ at 24 h. In conclusion cynaropicrin has selective cytotoxic effects on KYSE30 cells and we suggest its use in combination therapies with paclitaxel and 5-Fu, which would reduce the side effects of these conventional treatments.

Keywords: Esophageal cancer, Combination therapy, Cynaropicrin, Synergistic effects.

Introduction

The geographical distribution of esophageal cancer is variable in different parts of the world, reflecting the impact of environmental conditions, lifestyle and genetic factors on development of this disease (Mir *et al.*, 2005; Wang *et al.*, 2020). The incidence of this cancer is usually three to four times higher in men than women (Ferlay *et al.*, 2015; Torre *et al.*, 2015). In 2012, about 400,000 deaths from esophageal cancer and 456,000 new cases of this disease were documented (Ferlay *et al.*, 2013; Ferlay *et al.*, 2015., Liang *et al.*, 2017). Nearly 80% of new cases occur in less developed regions of the world (Enzinger *et al.*, 2003; Ferlay *et al.*, 2015; Wong *et al.*, 2018). Eastern Asia, eastern and southern Africa have the highest incidence of esophageal cancer and western Africa has the lowest (Torre *et al.*, 2015; Liang *et al.*, 2017; Wong *et al.*, 2018). This type of cancer is divided into two main forms with specific cause and distinct pathological features, including: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (Jemal *et al.*, 2011; Zhang *et al.*, 2012; Malhotra *et al.*, 2017). In 2012, nearly 90% of reported cases of esophageal cancer in the world were ESCC (Arnold *et al.*, 2015; Abnet *et al.*, 2018). In a region, often known as "esophageal cancer belt" extending from northern Iran through the Central Asian republics to the north central China, 91% cases of esophageal cancer are ESCC (Tran *et al.*, 2005; Akbari *et al.*, 2006; Siegel *et al.*, 2015; Komal *et al.*, 2019). ESCC is highly invasive and is usually diagnosed in advanced stages and thus it has a very poor prognosis (Quint *et al.*, 1995; Jemal *et al.*, 2005; Aghcheli *et al.*, 2011; Abnet *et al.*, 2018; Zhang *et al.*, 2020). The survival rate of ESCC in developed countries is 10 to 15% (Moyana *et al.*, 1996; Wang *et al.*, 2017; Abnet *et al.*, 2018). In advanced stages, that cancer has metastasized to the surrounding tissues such as lymph nodes, chemotherapy or combination of chemotherapy, radiotherapy and surgery are the preferred options for esophageal cancer treatment (Lagergren *et al.*, 2017; Hou *et al.*, 2019). However, despite the effectiveness of chemotherapy and radiotherapy, they often

51 cause very severe side effects (Qi *et al.*, 2010; Shapiro, 2016; Turcotte *et al.*, 2017). Studies
52 suggest that radiations used for radiotherapy, increase the cancer invasion power, tumor
53 migration and metastasis. In the case of chemotherapy, very high toxicity and low efficacy
54 have caused pessimism to this treatment (Camphausen *et al.*, 2001; Wild-Bode *et al.*, 2001;
55 Jung *et al.*, 2007; Huang *et al.*, 2017). Generally, the complexity of the formation and
56 development of esophageal cancer prevents effective treatment (Qi *et al.*, 2010; Yang *et al.*,
57 2012; Hu *et al.*, 2016).

58 During the past decades, use of targeted therapy has evolved greatly, however over the last
59 few years, this strategy has been geared towards combination therapy (Devita *et al.*, 1975;
60 Chesney *et al.*, 2000; Jukema and van der Hoorn, 2004; Weber and Noels, 2011; Gosh *et al.*,
61 2018), because the traditional use of a single drug for treatment of complex diseases, such as
62 cancer, is usually not effective. Using a combination of drugs, usually reduces their adverse
63 effects (Nowak *et al.*, 2016; Mokhtari *et al.*, 2017). The combination of drugs can lead to
64 additive, synergistic, antagonistic, or suppressive effects, however the best situation is a
65 combination that leads to synergism as it reduces the dosage and drug resistance, increases
66 the efficacy of treatment, and strengthens drug targeting. This type of treatment is considered
67 as a standard method for cancer therapy (Devita *et al.*, 1975; Jia *et al.*, 2009; Zhang *et al.*,
68 2012; Mokhtari *et al.*, 2017). It can also be stated that the biological effects of compounds in
69 a combined state are much greater than a single compound. The mixture of the compounds
70 has multiple bioactive effects due to having different targets (Devita *et al.*, 1975; Chesney *et*
71 *al.*, 2000; Jukema and van der Hoorn, 2004; Weber and Noels, 2011; Mokhtari *et al.*, 2017).

72 Natural products constitute safe, endless, and rich sources of drugs for treatment of various
73 diseases (Rates, 2001; Haefner, 2003; Butler, 2004; Raskin *et al.*, 2004; Cragg *et al.*, 2005;
74 Mishra *et al.*, 2011; Rey-Ladino *et al.*, 2011; Alam *et al.*, 2018). There has been a lot of
75 interest in developing alternative chemotherapy regimens that tend to use natural compounds,

76 especially medicinal herbs (Fu *et al.*, 2009; Kaur *et al.*, 2011; Mansoori *et al.*, 2019). From
77 155 anti-cancer drugs made since 1940, about 50% were either from natural products or their
78 derivatives (Kinghorn *et al.*, 2009; Ahmad *et al.*, 2016; Newman *et al.*, 2016; Elrayess *et al.*,
79 2019). This tendency to natural products is mostly due to the mentioned disadvantages of
80 conventional drugs, such as ineffectiveness, side effects and toxicity on normal cells (Fu *et*
81 *al.*, 2009; Kaur *et al.*, 2011; Mansoori *et al.*, 2019). Furthermore, natural compounds are safe
82 and can lead to development of more effective therapeutic agents (Rates, 2001; Mansoori *et*
83 *al.*, 2019). Natural secondary metabolites with herbal origin play an important role in cancer
84 chemotherapy (Mehhndiratta *et al.*, 2011; Seca *et al.*, 2018). Sesquiterpene lactones (SLs) are
85 a large and diverse group of natural products found in more than 100 flowering plant
86 families. The highest numbers of SLs have been extracted from the plants belonging to the
87 family Asteraceae (Heinrich *et al.*, 1998), which are rich in bioactive compounds (secondary
88 metabolites) such as polyacetylenes, diterpenes and SLs (Herz, 1977). These compounds
89 have many therapeutic activities including anti-inflammatory, anti-tumor, anti-microbial and
90 anti-viral properties (Baruah *et al.*, 1994; Zhang *et al.*, 2005; Xavier-ravi *et al.*, 2019). SLs
91 have been reported as promising anti-cancer agents with potentials in both chemotherapy and
92 chemoprevention (Akao *et al.*, 2013; Quintana *et al.*, 2018). They exert their properties by
93 inhibiting inflammatory responses, preventing metastasis, and inducing apoptosis (Zhang *et*
94 *al.*, 2005; Quintana *et al.*, 2018).

95 *Centaurea* L. with more than 700 species is one of the largest genera in the family Asteraceae
96 (Bensouici *et al.*, 2012). Members of this genus are spread all over the world (Forgo *et al.*,
97 2012). The main and most important compounds identified in this group are SLs (Cardona *et*
98 *al.*, 1994; Georgiadou *et al.*, 2000). *Centaurea* is well known in folk medicine for its anti-
99 microbial, anti-cancer, anti-diabetic, anti-rheumatic, anti-pyretic, anti-inflammatory,
100 stimulant, tonic, and some other properties (Garbacki *et al.*, 1999; Akkol *et al.*, 2009; Koca *et*

101 *al.*, 2009; Chougule *et al.*, 2012). According to several experiments, SLs are responsible for
102 the therapeutic properties of this genus (Chicca *et al.*, 2011). *Centaurea behen* is an annual
103 herb belonging to genus *Centaurea*. It is native to Iran, and is known as an Irano-Turanian
104 plant. In Iran it is known as Bahman Sefid. *C. behen* also grows in countries such as Iraq,
105 Pakistan, and India as well as North Africa and Europe (Khare, 2004; Mozaffarian, 2012;
106 Mosaddegh *et al.*, 2018). *C. behen* is used for traditional treatment of a number of diseases,
107 including cystic fibrosis, central nervous system (CNS) disorders, and kidney stone, and is
108 also used for its cardiogenic, sedative, anti-inflammatory, emmenagogue and aphrodisiac
109 properties (Yadava *et al.*, 2006, Mozaffarian, 2012; Mosaddegh *et al.*, 2018). A number of
110 SLs, including arguerin B, grosshemin and cynaropicrin, have been purified from this species
111 (Oksuz *et al.*, 1982). Researchers have proven that cynaropicrin has a wide variety of
112 biological activities including: anti-tumor (Zong *et al.*, 1994; Ha *et al.*, 2003; Muhammad *et*
113 *al.*, 2003; Cho *et al.*, 2004; Cho *et al.*, 2004b; Choi *et al.*, 2005; Kolli *et al.*, 2012; Salvador *et*
114 *al.*, 2008; Yang *et al.*, 2008; Butturini *et al.*, 2013; Liu *et al.*, 2019), anti-inflammatory (Cho *et*
115 *al.*, 1998; Cho *et al.*, 2000; Hayat *et al.*, 2019), anti-parasitic (Schinor *et al.*, 2004; Drab *et*
116 *al.*, 2005; Zimmermann *et al.*, 2012; da Silva *et al.*, 2013; Mokoka *et al.*, 2013), anti-bacterial
117 (Bachelier *et al.*, 2006), anti-photoaging, anti-oxidant (Tanaka *et al.*, 2013; Yamada *et al.*,
118 2015) and anti-spasmodic, through inhibiting the production of cytokines such as TNF α and
119 suppression of NF- κ B. Anti-cancer effects of cynaropicrin on various cancers such as
120 stomach, lung, breast and leukemia have been already reported (Cho *et al.*, 2004b).
121 According to the global burden of disease (GBD) statistics, esophageal cancer is among the
122 six most common cancers that has imposed heavy burdens on Iranian society (Majidi *et al.*,
123 2017), but despite these reports, little studies have been carried out on this cancer in Iran. In
124 the present study we aimed to: 1) evaluate the cytotoxic and anti-cancer properties of
125 cynaropicrin on ESCC cells for the first time, 2) determine the mechanism of cell death

induced by cynaropicrin, and 3) investigate its synergistic effects in combination with common drugs used in esophageal cancer chemotherapy, such as paclitaxel and 5-fluorouracil, in order to reduce the dose and subsequently, side effects of these medications.

Materials and Methods

Chemicals

Roswell Park Memorial Institute (RPMI)- 1640 medium, Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific and 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide (MTT) was obtained from Sigma Aldrich. Anti-cancer drugs used in this study include: paclitaxel (pac) from Actavis and 5-fluorouracil (5-Fu) from Elewe PHARMA. FITC-Annexin V Apoptosis Detection Kit with propidium iodide (PI) was purchased from BioLegend. Cynaropicrin was extracted and purified from *C. behen* (voucher specimens: No. 12405) in our previous work (Shakeri *et al.*, 2018).

Cell culture

Human esophageal cancer cell line (KYSE30) (Pasteur Institute, Iran) was cultured in RPMI-1640 with 10% FBS as a supplement, and human dermal fibroblast cell line (HDF) as normal cells (a generous gift from ACECR) were cultured in high glucose DMEM containing 15% FBS. Both cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO₂ (Lim *et al.*, 2000; Pan *et al.*, 2014).

Cell viability assay

Cell viability was evaluated by MTT assay. To do so, cells were cultured (9000 cells/well for KYSE30 and 10000 cells/well for HDF) in 96 well plates (Orange Scientific), and treated with various concentrations of cynaropicrin (KYSE30 and HDF cells), pac, 5-Fu, cynaropicrin-pac and cynaropicrin-5-Fu (only KYSE30 cells) for 24, 48 and 72 h. Finally, cells were incubated with 20 μ l MTT per well and after 4 h the absorbance of formazan crystals dissolved in dimethyl sulfoxide (DMSO) was measured at 570 nm by an ELISA plate reader (AWARENESS, USA).

Apoptosis detection

KYSE30 cells treated with 25 μ g/ml cynaropicrin for 15 h were dually stained with FITC-annexin V and PI for detection of apoptotic cells. Following BioLegend's instructions, treated cells were first washed with staining buffer. After harvesting and centrifugation, annexin V binding buffer was added and cells were stained with FITC-annexin V and PI for 15 min (in the dark). Finally, cells were subjected to flow cytometry to analyze the mechanism of cell death induced by cynaropicrin.

Investigating the synergistic effects of cynaropicrin with chemotherapy drugs

KYSE30 cells were treated with cynaropicrin, pac and 5-Fu, separately. Inhibitory concentration (IC_{50}) for each agent was evaluated by MTT assay after 24, 48 and 72 h. According to median effect method of Chou-Talalay and using $IC_{50\text{ Cyn}}/IC_{50\text{ drug}}$ relationship or inverse, the combination ratio was evaluated for cynaropicrin-pac and cynaropicrin-5Fu in all three time periods. KYSE30 cells were then treated with a combination of cynaropicrin-pac and cynaropicrin-5-Fu for 72 h. Synergistic effects of cynaropicrin with any of the used drugs was determined through evaluating the combination index (CI) and dose reduction

index (DRI) using the Calcu-Syn software (Biosoft, Cambridge, UK). In this regard, $CI < 1$ means synergistic effects, $CI = 1$ means additive effects and $CI > 1$ means antagonistic effects (Chou, 2010; Ashton, 2015).

Statistical analyses

Statistical analyses were performed using GraphPad Prism v. 6.07. Significant differences were ascertained by one-way ANOVA and multiple *t*-test. In the case of calculating the synergistic effects, Calcu-Syn software was used.

Results

Investigating the cytotoxic effects of cynaropicrin on KYSE30 cells

MTT assay was used to evaluate the cytotoxicity of cynaropicrin on esophageal cancer cells. To do so, cells were treated with different concentrations of the agent for 24, 48 and 72 h. IC_{50} values were calculated as 25.11, 15.39 and 9.94 $\mu\text{g/ml}$ equal to 72, 43 and 28 μM for 24, 48 and 72 h, respectively. Dose-response curves and IC_{50} values are shown in Fig. 1, indicating that cynaropicrin cytotoxicity on KYSE30 cells is concentration- and time-dependent. (Supplementary Graph 1, Comparison: 5 and Supplementary Image: 1, 2 and 3).

Fig. 1: A) Dose-response curves indicating the cytotoxic effects of cynaropicrin on KYSE30 cells. The graphs show the survival percentage of cells after treatment with different concentrations of cynaropicrin at 24, 48 and 72 h. The data are average of three repeats in each concentration with SEM. B) Comparing the IC_{50} values of cynaropicrin on KYSE30 cells at 24, 48 and 72 h. Columns are plotted with standard deviation. **** indicates the significance of the differences at the levels of $p < 0.0001$.

To evaluate the anti-cancer effects of cynaropicrin, the same assay was performed on HDF, as normal cells. Values of 58.06, 46.31 and 33.40 $\mu\text{g/ml}$ were calculated as IC_{50} of cynaropicrin at 24, 48 and 72 h, respectively. As indicated in Fig. 2, the results showed that cynaropicrin toxicity on this cell line is also concentration- and time- dependent. (Supplementary Graph 2, Comparison: 6 and Supplementary Image: 4, 5 and 6).

Fig. 2: A) Dose-response curves indicating the effects of cynaropicrin on HDF cells. The graphs show the survival percentage of cells after treatment with different concentrations of cynaropicrin at 24, 48 and 72 h. B) Comparing IC₅₀ values of cynaropicrin on HDF cells at 24, 48 and 72 h. Columns are plotted with standard deviation. **** indicates the significance of the differences at the levels of $p < 0.0001$.

Comparing the results between the two cell lines as shown in Fig. 3, indicated a selective cytotoxicity on the cancerous cells, which may confirm the anti-cancer effects of cynaropicrin. (Supplementary Comparison: 7).

Fig. 3: Comparing the IC₅₀ values of cynaropicrin on KYSE30 and HDF cells at 24, 48 and 72 h. **** indicates significance of differences at the level of $p < 0.0001$.

Cynaropicrin induces apoptotic cell death

To investigate the cell death mechanism induced by cynaropicrin, flow cytometric analysis was performed after staining with FITC-annexin V and PI. Cells were treated with the calculated IC₅₀ value of cynaropicrin for 24 h, equal to 25 µg/ml, and stained after 15 h. A control group was also treated with DMSO to find out the effects of solvent on induction of apoptosis. Pac was used as a positive control and untreated cells were considered as negative control. Flow cytometry results are presented in Fig. 4. (Supplementary A, C and D).

A

B

C

D

Fig. 4: Cynaropicrin induces apoptosis in KYSE30 cells as shown with PI and FITC-annexin V double staining and flow cytometry. A) Untreated cells, B) cells treated with DMSO, C) cells treated with paclitaxel, and D) cells treated with cynaropicrin.

The diagram of treated cells with cynaropicrin shows the presence of the majority of cells in quarter 3, which indicates the occurrence of apoptosis in cells caused by cynaropicrin. The cells in this quarter are annexin V⁺ and PI⁻.

Cynaropicrin had synergistic effects with paclitaxel and 5-Fu

The median effect method of Chou-Talalay was used for investigating the synergistic effects of cynaropicrin with different drugs. To do so, acquiring data such as the IC₅₀ and slope of dose-response diagrams for cynaropicrin, pac and 5-Fu at three time periods was necessary. As shown in Fig. 5, IC₅₀ values estimated for pac, were equal to 7.93, 5.92 and 3.90 µg/ml and for 5-Fu, 79.98, 25.22 and 15.16 µg/ml at 24, 48 and 72 h, respectively. (Supplementary Gragh3,4 and Supplementary Image: 7, 8, 9, 10, 11 and 12).

A

B

Fig. 5: Dose-response curves of A) pac and B) 5-Fu on KYSE30 cells. The graphs show the survival percentages of cells after treatment with different concentrations of drugs at 24, 48 and 72 h.

The results indicated that pac had cytotoxic effects on KYSE30 cells in a time and concentration-dependent manner. Moreover, 5-Fu showed similar but weaker effects, especially on the first day of treatment. The combination experiments for cynaropicrin and the two drugs were designed and cells were treated for 24, 48 and 72 h, based on the principles of the median effect method. The results of both combinations, in all three time periods, are presented in Figs. 6 and 7 for pac and 5-Fu, respectively. Diagrams were drawn in the form of combination and dose reduction indices. With regard to pac-cyn combination, the graphs represented an additive effect at low concentrations and an antagonistic effect at high concentrations of combination within 24 h. A synergistic effect at 48 h and a moderate synergism at 72 h were observed. In both time periods, the CI value had been reduced at higher concentrations and the synergism was strengthened. The results of the cynaropicrin-pac combination in three periods are listed in table 1 in three sections A, B and C. (Supplementary S1, S2 and S3).

A

B

C

D

E

F

Fig. 6: A, C and E): Combination index diagrams show the simultaneous effects of pac and cynaropicrin on KYSE30 cells at 24, 48 and 72 h, respectively. B, D and F): Dose reduction diagrams express a multiplier reduction in the dose of pac and cyn in a combination treatment over 24, 48 and 72 h. CI: Combination Index, Fa: Fraction affected, CI doesnot have unit.

Table 1: CI and the DRI related to the combination of cyn-pac at A) 24, B) 48, C) 72 h.

A

24 h	CI value	DRI Cyn	DRI Pac
IC ₅₀	1.02	1.93	1.96
IC ₇₅	1.05	1.94	1.85
IC ₉₀	1.08	1.94	1.75
IC ₉₅	1.10	1.94	1.69

B

48 h	CI values	DRI Cyn	DRI Pac
IC ₅₀	0.70	2.72	2.72
IC ₇₅	0.65	3.12	2.93
IC ₉₀	0.61	3.58	2.93
IC ₉₅	0.59	3.93	2.93

C

72 h	CI value	DRI Cyn	DRI Pac
IC ₅₀	0.87	2.53	2.06
IC ₇₅	0.80	2.77	2.24
IC ₉₀	0.73	3.02	2.43
IC ₉₅	0.69	3.22	2.58

The combination of cynaropicrin and 5-Fu demonstrated a very strong synergism, so that CI= 0.13 and DRI for both substances in the IC₅₀ was about 15. However, at higher concentrations, the observed synergism was very weak, which ultimately ends to antagonism. The results for this combination at 48 and 72 h indicated a synergism and a moderate synergism, respectively.

In Fig. 7, the CI and the DRI charts referring to cyn-5-Fu combinations at 24, 48 and 72 h are presented. The results of the cynaropicrin-5-Fu combination in three periods are listed in table 2 in three sections A, B and C. (Supplementary S4, S5 and S6).

A

B

C

D

E

F

Fig. 7: A, C and E): Combination index diagrams showing the effects of 5-Fu and cynaropicrin on each other at 24, 48 and 72 h. B, D and F): Dose reduction diagrams, expressing a multiplier reduction in the dose of 5-Fu and Cyn in a combination treatment over 24, 48 and 72 h. CI: Combination Index, Fa: Fraction affected, CI does not have unit.

Table 2: CI and the DRI related to the combination of cyn-5-Fu at A) 24, B) 48, C) 72 h.

A

24 h	CI value	DRI Cyn	DRI 5-Fu
IC ₅₀	0.13	15.26	15.07
IC ₇₅	0.37	5.03	5.75
IC ₉₀	1.07	1.66	2.19
IC ₉₅	2.15	0.78	1.14

B

48 h	CI value	DRI Cyn	DRI 5-Fu
IC ₅₀	0.36	5.92	5.18
IC ₇₅	0.40	4.56	5.27
IC ₉₀	0.47	3.51	5.37
IC ₉₅	0.52	2.93	5.44

C

72 h	CI value	DRI Cyn	DRI 5-Fu
IC ₅₀	0.71	3.01	2.61
IC ₇₅	0.75	3.11	2.29
IC ₉₀	0.80	3.21	2.01
IC ₉₅	0.84	3.28	1.83

Table 2: CI and the DRI related to the combination of cyn-5-Fu at A) 24, B) 48, and C) 72 h.

Discussion

The high incidence and mortality rate of esophageal cancer, which is one of the common cancers of the digestive system in Asia (Ferlay *et al.*, 2010), indicate the serious threats of this malignancy (Napier *et al.*, 2014). The absence of a comprehensive diagnostic system leads to late detection, poor prognosis and high mortality rates (Polednak, 2003; Qureshi *et al.*, 2009; Pourhoseingholi *et al.*, 2015). Some predictions suggest a decrease in the incidence of cancer in the coming decades, but it does not include esophageal cancer. The incidence of esophageal cancer is expected to increase by 140% up to 2025 (Lambert *et al.*, 2007).

In the present study, the toxicity and anti-cancer effects of cynaropicrin were investigated on KYSE30 cells and the mechanism of cell death induced by this compound was examined. The synergistic effects of cynaropicrin with common chemotherapeutic drugs used for esophageal cancer, paclitaxel and 5-Fu, were also investigated and calculated by Chou-Talalay median effect method. The results indicated significant differences ($p < 0.0001$) in cytotoxic effects of cynaropicrin on normal HDF cells compared to cancerous cell line, which proves selective toxicity and anti-cancer effects of this compound on KYSE30 cells.

As mentioned earlier, many studies have been carried out on cynaropicrin in which several investigations are related to cytotoxic and anti-cancer effects of this compound. Some researchers have focused only on cytotoxic effects of cynaropicrin (Choi *et al.*, 2005; Yang *et al.*, 2008; Bruno *et al.*, 2005; Ha *et al.*, 2003; Kang *et al.*, 2007 and Butturini *et al.*, 2013). In these studies, cytotoxic effects of cynaropicrin were proven on different cell lines including prostate, breast, stomach, colon, lung, ovary and cervix cancerous cells and also myeloma cells. The lowest and highest reported IC_{50} values were 0.83 μ M for HCT15 (colon cancer) and 24.51 μ M for A549 (lung cancer), respectively. In none of these studies, the selective anti-cancer effects of cynaropicrin were investigated.

522 In a study by Cho and colleagues (2004b), several leukocyte cancer cell lines including U937,
523 1-EO1 and Jurkat T cells were treated with cynaropicrin and its toxic effects were confirmed.
524 The treatment was also performed on HDF-1 and Chang liver cells (human liver cells) as
525 normal cell lines. The significant difference observed between the IC₅₀ values of cancerous
526 and normal cells confirms the anti-cancer effects of this compound (Cho *et al.*, 2004b). In a
527 similar study, various cancer cell lines were treated with cynaropicrin. The lowest and highest
528 IC₅₀ values were related to SK-MEL (melanoma) equal to 5.77μM and SK-OV-3 (ovary
529 cancer) equal to 18.18 μM, respectively. VERO cell line (kidney epithelial cells from African
530 green monkey) as normal cells, was used to confirm the anti-cancer effects of cynaropicrin.
531 No significant difference was observed between its IC₅₀ values on normal and cancerous cells
532 (Muhammad *et al.*, 2003). It can be concluded that VERO cells were not an appropriate
533 control in this study. The findings of these reports are in agreement with the results obtained
534 in present study.

535 Chen and colleagues (2007) proved that the activation of EGFR-encoding gene contributes to
536 the creation and progression of ESCC. The role of inhibiting this pathway in the treatment of
537 esophageal cancer was discovered using erlotinib and afatinib inhibitors. For this purpose,
538 seven different ESCC cell lines were examined. Observations indicated that these drugs
539 inhibited the pathway and led to a decrease in the growth of cancerous cells. However,
540 KYSE30, TE8 and KYSE250 were introduced as cell lines which significantly had less
541 growth inhibition, and were more resistant than other ESCC cell lines used in their study
542 (Chen *et al.*, 2017). This result can be a reason for the numerical difference between IC₅₀
543 values of cynaropicrin on KYSE30 cells compared with other cancerous cell lines.

544 The occurrence of apoptosis after treatment with cynaropicrin was confirmed by flow
545 cytometry. Several other studies have also shown the apoptosis inducing effects of
546 cynaropicrin in different cell lines. For example, according to Cho *et al.* the production of

547 reactive oxygen species by cynaropicrin led to induction of apoptosis. To prove this, cells
548 were treated simultaneously with cynaropicrin and two scavengers of reactive oxygen species
549 including L-cysteine and N-acetyl-L-cysteine. The two scavengers inhibited the
550 morphological changes and DNA fragmentation induced by cynaropicrin (Cho *et al.*, 2004b).
551 Moreover, in a study by Butturini *et al.* cynaropicrin was considered as an inhibitor of
552 STAT3 activation and IL-6 production stimulus. They showed that cynaropicrin as the
553 receptor of the Michaelis-Menten reaction, induces the addition of glutathione to STAT3 and
554 inhibits this transcription factor. The inhibition of STAT3 leads to suppressing the expression
555 of two anti-apoptotic genes, including BCL2 and Survivin in DU 145 cells. STAT3 is active
556 in a variety of cancers and plays an important role in inhibition of apoptosis and inducing
557 drug resistance (Butturini *et al.*, 2013).

558 As noted above, Chou-Talalay method was used to investigate the combination effects of
559 cynaropicrin with pac and 5-Fu drugs. The reason for this selection is the advantages of this
560 method including: detection of various types of behaviors in combination (synergism,
561 additive and antagonism), significant reduction in drug consumption, time saving, estimation
562 of the behavior of materials in combination with the lowest number of data, presenting results
563 numerically and independent of unit, and in particular, being functional at both *in vitro* and *in*
564 *vivo* levels (Chou, 2006; Chou, 2008). Additive effects were observed in the combination of
565 cynaropicrin with pac using this method at 24 h. The strongest synergistic effects were
566 revealed at 48 h. DRI for pac was about three times, and for cynaropicrin was about four
567 times. These synergistic effects were also observed at 72 h at which DRI for pac was greater
568 than two times and for cynaropicrin it was higher than three times. It must be noted that
569 having a dose reduction in combination does not merely mean synergistic effects. So that,
570 even in the case of minor antagonism, there is a possibility of dose reduction. Therefore, CI is
571 the primary reference for the diagnosis of synergistic effects. All in all, cynaropicrin had a

572 synergistic effect in combination with pac in a time-dependent manner. In the combination of
573 cynaropicrin with 5-fluorouracil in IC_{50} , the CI was equal to 0.13 with a DRI= of about 15,
574 that indicate a very strong synergistic effect. However, our data showed that with an increase
575 in IC, the CI increases. So that, in IC_{95} the CI reached over two, which indicates the
576 antagonistic effect. Hence, cynaropicrin and 5-Fu have the most synergistic effects at lower
577 concentrations. At 48 h, this combination also showed a good synergistic effect in IC_{50} in
578 which the CI was equal to 0.36. Regarding the remaining synergistic effects, even at IC_{95} at
579 48 h, it can be concluded that the synergistic effects of cynaropicrin and 5-Fu at high
580 concentrations are time-dependent. At 72 h, synergistic effects were observed for all
581 concentrations of the combination. To summarize, combination of both drugs with
582 cynaropicrin had the most logical synergistic effects within 48 h. However, the strongest
583 synergistic effects on the combination of cynaropicrin and 5-Fu was observed at 24 h.

584 Study of Butturini *et al.* (2013) is the only trial in which the combination of cynaropicrin with
585 chemotherapy drugs was examined. In this study, the effects of cynaropicrin in combination
586 with cisplatin and docetaxel were investigated on a prostate cancer cell line (DU 145). In both
587 cases, the synergistic effects of cynaropicrin were observed (Butturini *et al.*, 2013). In
588 another study, the effects of DMSO on platinum compounds such as cisplatin and carboplatin
589 were investigated (Hall *et al.*, 2014). As a result, it was reported that DMSO reacts with
590 platinum and prevents the toxicity of these compounds (Hall *et al.*, 2014). According to this
591 result, the cisplatin combination with cynaropicrin in the study of Butturini and colleagues
592 (2013), requires further approval with another suitable solvent for cynaropicrin. Based on the
593 Chou-Talalay method, the smaller CI will have a greater DRI, but in the case of combination
594 of docetaxel with cynaropicrin in the latest study, the result is quite the opposite; when the
595 strongest synergistic effect was observed, there was the lowest dose reduction and in the
596 weakest synergistic effect, the highest reduction in the dosage were recorded, which does not

seem to be logical (Butturini *et al.*, 2013). Therefore, the results of the combination of docetaxel and cynaropicrin also need to be reviewed.

Conclusion

To conclude, the present study reported cynaropicrin as a potent candidate with anti-cancer properties for treatment of ESCC. It has a very high potential for combinational therapy which can reduce the dose of chemotherapy drugs and subsequently reduce their side effects. Nevertheless, further studies are needed to investigate the effects of cynaropicrin on other cancer cell lines, as well as its synergistic effects with other chemotherapy drugs in both *in vitro* and *in vivo* models.

Acknowledgements

Authors would like to express their sincere thanks to Dr. Fatemeh Homaei Shandiz, Dr. Kordiyeh Hamidi, Nahid Arghiani and Mahboobeh Kazemi for their scientific and technical supports which greatly improved the content.

Funding

This research was supported by a grant (no: 43291) from Ferdowsi University of Mashhad.

Authors Contributions

M.M.M.and A.R.B. conceived and designed the experiments, and supervised the project; S.N. conducted the experiments and wrote the manuscript; S.N. and N.G. analyzed the data; M.I. and A.S.extracted and purified the tested plant composition; M.M.M. and A.S. proofread the manuscript. All authors discussed the results and commented on the manuscript. The authors declare that all data were generated in-house and that no paper mill was used.

Declarations

Consent to participate:

The authors declare consent to participate in this study.

Consent for publication:

The authors declare consent to publish this study.

Conflict of interest:

The authors declare that they have no conflict of interest.

Ethics approval:

This article does not contain any studies with human participants or animals performed by any of the authors.

References

- Abnet, C. C., Arnold, M., & Wei, W. Q. (2018). Epidemiology of esophageal squamous cell carcinoma. *Gastroenterology*, 154(2), 360-373.
- Ahmad, R., Ahmad, N., Naqvi, A. A., Shehzad, A., & Al-Ghamdi, M. S. (2016). Role of traditional Islamic and Arabic plants in cancer therapy. *Journal of Traditional and Complementary Medicine*, 7(2), 195-204.
- Aghcheli, K., Marjani, H. A., Nasrollahzadeh, D., Islami, F., Shakeri, R., Sotoudeh, M., ... & Mohtashami, S. (2011). Prognostic factors for esophageal squamous cell carcinoma—a population-based study in Golestan Province, Iran, a high incidence area. *PLoS One*, 6(7), e22152.
- Akao, Y., Tanaka, Y. T., Tanaka, K., Kojima, H., Hamada, T., Masutani, T. & Tsuboi, M. (2013). Cynaropicrin from *Cynara scolymus* L. suppresses photoaging of skin by inhibiting the transcription activity of nuclear factor-kappa B. *Bioorganic & Medicinal Chemistry Letters*. 23:518–523.
- Akbari, M. R., Malekzadeh, R., Nasrollahzadeh, D., Amanian, D., Sun, P., Islami, F., & Ghadirian, P. (2006). Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran. *International Journal of Cancer*, 119(5), 1047-1051.
- Akkol, E. K., Arif, R., Ergun, F., & Yesilada, E. (2009). Sesquiterpene lactones with antinociceptive and antipyretic activity from two *Centaurea* species. *Journal of Ethnopharmacology*, 122(2), 210-215.
- Alam, F., Islam, M. A., Kamal, M. A., & Gan, S. H. (2018). Updates on managing type 2 diabetes mellitus with natural products: towards antidiabetic drug development. *Current Medicinal Chemistry*, 25(39), 5395-5431.
- Arnold, M., Soerjomataram, I., Ferlay, J., & Forman, D. (2015). Global incidence of oesophageal cancer by histological subtype in 2012. *Gastroenterology*, 64(3), 381-387.
- Ashton, J. C. (2015). Drug combination studies and their synergy quantification using the Chou-Talalay method letter. *Cancer Research*, 75(11), 2400-2400.
- Bachelier, A., Mayer, R., & Klein, C. D. (2006). Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. *Bioorganic & Medicinal Chemistry Letters*, 16(21), 5605-5609.
- Baruah, N. C., Sarma, J. C., Barua, N. C., Sarma, S., & Sharma, R. P. (1994). Germination and growth inhibitory sesquiterpene lactones and a flavone from *Tithoni adiversifolia*. *Phytochemistry*, 36(1), 29-36.
- Bensouici, C., Kabouche, A., Kabouche, Z., Touzani, R., & Bruneau, C. (2012). Sesquiterpene lactones and flavonoids from *Centaurea foucauldiana*. *Chemistry of Natural Compounds*, 48(3), 510-511.

- Bruno, M., Rosselli, S., Maggio, A., Raccuglia, R. A., Bastow, K. F., Wu, C. C., & Lee, K. H. (2005). Cytotoxic activity of some natural and synthetic sesquiterpene lactones. *Planta Medica*, 71(12), 1176-1178.
- Butler, M. S. (2004). The role of natural product in chemistry in drug discovery. *Journal of Natural Products*. 67: 2141–2153.
- Butturini, S., Mariotto, E., Alessandra Carcereri de Prati, Chiavegato, G., Rigo, A., Cavalieri, E. & Darra, E. (2013). Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. *Free Radical Biology and Medicine*, 65, 1322-1330.
- Camphausen, K., Moses, M. A., Beecken, W. D., Khan, M. K., Folkman, J., O'Reilly, M. S. (2001). Radiation therapy to a primary tumor accelerates metastatic growth in mice. *Cancer Research*. 61: 2207-11.
- Cardona, L., Garcia, B., Navarro, F. I., & Pedro, J. R. (1994). Sesquiterpene lactones from *Centaurea paui*. *Natural Product Letters*, 5(1), 47-54.
- Chen, L., & Pan, J. (2017). Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. *British Journal of Pharmacology*, 174(15), 2427-2443.
- Chesney, M. A., Morin, M., and Sherr, L. (2000). Adherence to HIV combination therapy. *Social Science and Medicine*. 50: 1599–1605.
- Chicca, A., Tebano, M., Adinolfi, B., Ertugrul, K., Flamini, G., & Nieri, P. (2011). Anti-proliferative activity of aguerin B and a new rare nor-guaianolide lactone isolated from the aerial parts of *Centaurea deflexa*. *European Journal of Medicinal Chemistry*, 46(7), 3066-3070.
- Cho, J. Y., Baik, K. U., Jung, J. H., & Park, M. H. (2000). In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from *Saussurea lappa*. *European Journal of Pharmacology*, 398(3), 399-407.
- Cho, J. Y., Kim, A. R., Joo, H. G., Kim, B. H., Rhee, M. H., Yoo, E. S., ... & Jung, J. H. (2004). Cynaropicrin, a sesquiterpene lactone, as a new strong regulator of CD29 and CD98 functions. *Biochemical and Biophysical Research Communications*, 313(4), 954-961.
- Cho, J. Y., Kim, A. R., Jung, J. H., Chun, T., Rhee, M. H. & Yoo, E. S. (2004b). Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines. *European Journal of Pharmacology*, 492(2), 85-94.
- Cho, J. Y., Park, J., Yoo, E. S., Baik, K. U., Jung, J. H., Lee, J., & Park, M. H. (1998). Inhibitory effect of sesquiterpene lactones from *Saussurea lappa* on tumor necrosis factor- α production in murine macrophage-like cells. *Planta Medica*, 64(07), 594-597.
- Choi, S. Z., Choi, S. U. & Lee, K. R. (2005). Cytotoxic sesquiterpene lactones from *Saussurea calciccola*. *Archives of Pharmacal Research*, 28(10), 1142-1146.

- Chou, T. C. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Research*, 70(2), 440-446.
- Chou, T. C. (2008). The Mass-Action-Law Based GPS Concept for Bio-Informatics, 1-1.
- Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacological Reviews*, 58(3), 621-681.
- Chougule, P., Pawar, R., Limaye, D., Joshi, Y. M., & Kadam, V. (2012). In-vitro antioxidant activity of ethanolic extract of *Centaurea behen*. *Journal of Applied Pharmaceutical Science*, 02, 106-110.
- Cragg, G. M., Newman, D. J. (2005). Biodiversity: A continuing source of novel drug leads. *Pure and Applied Chemistry*. 77: 7–24.
- da Silva, C. F., Batista, D. D. G. J., De Araujo, J. S., Batista, M. M., Lionel, J., de Souza, E. M., ... & Zimmermann, S. (2013). Activities of psilostachyin A and cynaropicrin against *Trypanosoma cruzi* in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, 57(11), 5307-5314.
- Devita, V. T., Young, R. C., & Canellos, G. P. (1975). Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. *Cancer*, 35(1), 98-110.
- Drab, A. I., Nurmukhametova, K. A., Pak, R. N., & Adekenov, S. M. (2005). Antiopisthorchotic action of *Saussurea salsa* extract. *Pharmaceutical Chemistry Journal*, 39(8), 425-427.
- Elrayess, R. A., & El-Hak, H. N. G. (2019). Anticancer natural products: A review. *Cancer Studies Molecular Medicine Open Journal*. 5(1), 14–25.
- Enzinger, P. C., & Mayer, R. J. (2003). Esophageal cancer. *New England Journal of Medicine*, 349(23), 2241-2252.
- Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*, 127:2893-917.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5): E359-E386.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., & Mathers, C. (2013). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
- Forgo, P., Zupko, I., Molnar, J., Vasas, A., Dombi, G., & Hohmann, J. (2012). Bioactivity-guided isolation of antiproliferative compounds from *Centaurea jacea* L. *Fitoterapia*, 83(5), 921-925.

- Fu, P. P., Chiang, H. M., Xia, Q., Chen, T. A. O., Chen, B. H., Yin, J. J., ... & Yu, H. (2009). Quality assurance and safety of herbal dietary supplements. *Journal of Environmental Science and Health Part C*, 27(2), 91-119.
- Garbacki, N., Gloaguen, V., Damas, J., Bodart, P., Tits, M., & Angenot, L. (1999). Anti-inflammatory and immunological effects of *Centaurea cyanus* flower-heads. *Journal of Ethnopharmacology*, 68(1-3), 235-241.
- Georgiadou, E., Skaltsa, H., Lazari, D., Garcia, B., & Harvala, C. (2000). A novel eudesmanolide from *Centaurea thessala* Hausskn. Ssp. *Drakiensis* (Freyn & Sint.) Georg. *Natural Product Letters*, 14(3), 167-173.
- Ha, T. J., Jang, D. S., Lee, J. R., Lee, K. D., Lee, J., Hwang, S. W., Jung, H. J., Nam, S. H., Park, K. H. & Yang, M. S. (2003). Cytotoxic effects of sesquiterpene lactones from the flowers of *Hemisteptia lyrata* B. *Archives of Pharmacol Research*, 26(11): 925-928.
- Haefner, B. (2003). Drugs from the deep: Marine natural products as drug candidates. *Drug Discovery Today*. 8: 536-544.
- Hall, M. D., Telma, K. A., Chang, K. E., Lee, T. D., Madigan, J. P., Lloyd, J. R., ... & Gottesman, M. M. (2014). Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. *Cancer Research*, 74(14), 3913-3922.
- Hayata, M., Watanabe, N., Kamio, N., Tamura, M., Nodomi, K., Tanaka, K., ... & Ueda, K. (2019). Cynaropicrin from *Cynara scolymus* L. suppresses *Porphyromonas gingivalis* LPS-induced production of inflammatory cytokines in human gingival fibroblasts and RANKL-induced osteoclast differentiation in RAW264. 7 cells. *Journal of Natural Medicines*, 73(1), 114-123.
- Heinrich, M., Robles, M., West, J. E., Ortiz de Montellano, B. R. & Rodriguez, E. (1998). Ethnopharmacology of Mexican asteraceae (*compositae*). *Annual Review of Pharmacology and Toxicology*, 38(1): 539-565.
- Herszenyi, L., Tulassay, Z. (2010). Epidemiology of gastrointestinal and liver tumors. *European Review for Medical and Pharmacological Sciences*, 14:249-258.
- Herz, W. (1977). Sesquiterpene lactones in the *Compositae*. Heywood, V, H, Harborne, J, B,, Turner, B, L ed (s). *The Biology and Chemistry of the Compositae*, 1, 337-357.
- Hou, H., Meng, Z., Zhao, X., Ding, G., Sun, M., Wang, W., & Wang, Y. (2019). Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. *Frontiers in Oncology*, 9, 548.
- Huang, C. Y., Ju, D. T., Chang, C. F., Reddy, P. M., & Velmurugan, B. K. (2017). A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. *Biomedicine*, 7(4).
- Hu, X. Q., Sun, Y., Lau, E., Zhao, M., & Su, S. B. (2016). Advances in synergistic combinations of Chinese herbal medicine for the treatment of cancer. *Current Cancer Drug Targets*, 16(4), 346-356.

- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. *CA: A Cancer Journal for Clinicians*, 61(2), 69-90.
- Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., et al. (2005). Cancer statistics. *CA: A Cancer Journal for Clinicians*, 55:10–30.
- Jia, J., Zhu, F., Ma, X., et al. (2009). Mechanisms of drug combinations: interaction and network perspectives. *Nature Reviews Drug Discovery*. 8: 111–28.
- Jukema, J. W., andvanderHoorn, J. W. (2004). Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. *Expert Opinion on Pharmacotherapy*. 5: 459–468.
- Jung, J. W., Hwang, S. Y., Hwang, J. S., Oh, E. S., Park, S., Han, I. O. (2007). Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. *European Journal of Cancer*. 43: 1214-24.
- Kang, K., Lee, H. J., Kim, C. Y., Lee, S. B., Tunsag, J., Batsuren, D., & Nho, C. W. (2007). The chemopreventive effects of *Saussurea salicifolia* through induction of apoptosis and phase II detoxification enzyme. *Biological and Pharmaceutical Bulletin*, 30(12), 2352-2359.
- Kaur, R., Kapoor, K., & Kaur, H. (2011). Plants as a source of anticancer agents. *Journal of Natural Product and Plant Resources*, 1(1), 119-124.
- Khare, C. P. (2004). Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany. *Springer Science & Business Media*.
- Kinghorn, A. D., Chin, Y. W., & Swanson, S. M. (2009). Discovery of natural product anticancer agents from biodiverse organisms. *Current Opinion in Drug Discovery & Development*, 12(2), 189.
- Koca, U., Toker, G., & Akkol, E. K. (2009). Assessment of the extracts of *Centaurea chihatcheffii* Fischer for anti-inflammatory and analgesic activities in animal models. *Tropical Journal of Pharmaceutical Research*, 8(3).
- Kolli, E. H., Leon, F., Benayache, F., Estevez, S., Quintana, J., Estevez, F., ... & Benayache, S. (2012). Cytotoxic sesquiterpene lactones and other constituents of *Centaurea omphalotricha*. *Journal of the Brazilian Chemical Society*, 23(5), 977-983.
- Komal, K., Chaudhary, S., Yadav, P., Parmanik, R., & Singh, M. (2019). The therapeutic and preventive efficacy of curcumin and its derivatives in esophageal cancer. *Asian Pacific Journal of Cancer Prevention*, 20(5), 1329.
- Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017). Oesophageal cancer. *The Lancet*, 390(10110), 2383-2396.
- Lambert, R., Hainaut, P. (2007). The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. *Best Practice & Research: Clinical Gastroenterology*, 21:921–945.

- Liang, H., Fan, J. H., & Qiao, Y. L. (2017). Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. *Cancer Biology & Medicine*, 14(1), 33-41.
- Lim, I. K., Hong, K. W., Kwak, I. H., Yoon, G., & Park, S. C. (2000). Cytoplasmic retention of p-Erk1/2 and nuclear accumulation of actin proteins during cellular senescence in human diploid fibroblasts. *Mechanisms of Ageing and Development*, 119(3), 113-130.
- Liu, T., Zhang, J., Han, X., Xu, J., Wu, Y., & Fang, J. (2019). Promotion of HeLa cells apoptosis by cynaropicrin involving inhibition of thioredox in reductase and induction of oxidative stress. *Free Radical Biology and Medicine*, 135, 216-226.
- Majidi, A., Salimzadeh, H., Beiki, O., Delavari, F., Majidi, S., Delavari, A., & Malekzadeh, R. (2017). Cancer research priorities and gaps in Iran: the influence of cancer burden on cancer research outputs between 1997 and 2014. *Public Health*, 144, 42-47.
- Malhotra, G. K., Yanala, U., Ravipati, A., Follet, M., Vijayakumar, M., & Are, C. (2017). Global trends in esophageal cancer. *Journal of Surgical Oncology*, 115(5), 564-579.
- Mansoori, B., Mohammadi, A., Doustvandi, M. A., Mohammadnejad, F., Kamari, F., Gjerstorff, M. F., ... & Hamblin, M. R. (2019). Photodynamic therapy for cancer: Role of natural products. *Photodiagnosis and Photodynamic Therapy*, 26, 395-404.
- Mehndiratta, S., Kumar, S., Meena, A. K., Koul, S., Suri, O., & Dhar, K. L. (2011). A Review on plants a useful source of anti-cancer drugs. *Journal of Pharmacy Research*, 4, 264-71.
- Mir, M. M., Dar, N. A., Gochhait, S., Zargar, S. A. & Ahangar, A. G. (2005) p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high incidence area. *International Journal of Cancer* 116: 62-68.
- Mishra, B. B., Tiwari, V. K. (2011). Natural products: An evolving role in future drug discovery. *European Journal of Medicinal Chemistry*. 46: 4769–4807.
- Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. *Oncotarget*, 8(23), 38022.
- Mokoka, T. A., Xolani, P. K., Zimmermann, S., Hata, Y., Adams, M., Kaiser, M., ... & Brun, R. (2013). Antiprotozoal screening of 60 South African plants, and the identification of the antitrypanosomal germacranolides schkuhrin I and II. *Planta Medica*, 79(14), 1380-1384.
- Mosaddegh, M., Tavakoli, M., & Behzad, S. (2018). Constituents of the aerial parts of *Centaurea behen*. *Chemistry of Natural Compounds*, 54(5), 1015-1017.
- Moyana, T. N., Janoski, M. (1996). Recent trends in the epidemiology of esophageal cancer. Comparison of epidermoid- and adenocarcinomas. *Annals of Clinical & Laboratory Science*, 26:480-486.
- Mozaffarian, V. (2012). Identification of medicinal and aromatic plants of Iran. *Farhang Moaser Publishers*.

- Muhammad, I., Takamatsu, S., Mossa, J. S., El-Feraly, F. S., Walker, L. A. & Clark, A. M. (2003). Cytotoxic sesquiterpene lactones from *Centaurothamnus maximus* and *Vicoapentanema*. *Phytotherapy Research* 17(2): 168-173.
- Napier, K. J., Scheerer, M., & Misra, S. (2014). Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. *World Journal of Gastrointestinal Oncology*, 6(5), 112–120.
- Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products*, 79(3), 629-661.
- Nowak-Sliwinska, P., Weiss, A., Ding, X., Dyson, P. J., Van Den Bergh, H., Griffioen, A. W., & Ho, C. M. (2016). Optimization of drug combinations using feedback system control. *Nature Protocols*, 11(2), 302-315.
- Oksuz, S., Ulubelen, A., Aynechi, Y., & Wagner, H. (1982). A guaianolide from *Centaurea behen*. *Phytochemistry*, 21(11), 2747-2749.
- Pan, F., Yao, J., Chen, Y., Zhou, C., Geng, P., Mao, H., & Fang, X. (2014). A novel long non-coding RNA FOXCUT and mRNA FOXC1 pair promote progression and predict poor prognosis in esophageal squamous cell carcinoma. *International Journal of Clinical and Experimental Pathology*, 7(6), 2838.
- Pourhoseingholi, M. A., Vahedi, M., Baghestani, A.R. (2015). Burden of gastrointestinal cancer in Asia; an overview. *Gastroenterol Hepatol Bed Bench*, 8: 19-27.
- Polednak, A. P. (2003). Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. *International Journal of Cancer*, 105: 98-100.
- Qi, F., Li, A., Inagaki, Y., Gao, J., Li, J., Kokudo, N., ... & Tang, W. (2010). Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer. *Bioscience Trends*, 4(6), 297-307.
- Quint, L. E., Hepburn, L. M., Francis, I. R., Whyte, R. I., & Orringer, M. B. (1995). Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. *Cancer*, 76(7), 1120-1125.
- Quintana, J., & Estevez, F. (2018). Recent advances on cytotoxic sesquiterpene lactones. *Current Pharmaceutical Design*, 24(36), 4355-4361.
- Qureshi, I., Shende, M., Luketich, J.D. (2009). Surgical palliation for Barrett's esophagus cancer. *Surgical Oncology Clinics of North America*, 18:547-60.
- Raskin, I., Ripoll, C. (2004). Can an apple a day keep the doctor away? *Current Pharmaceutical Design*. 10: 3419-29.
- Rates, S. M. K. (2001). Plants as source of drugs. *Toxicon*, 39(5), 603-613.

Rey-Ladino, J., Ross, A. G., Cripps, A. W., McManus, D. P., Quinn, R. (2011). Natural products and the search for novel vaccine adjuvants. *Vaccine*. 29: 6464–6471.

Sadjadi, A., Nouraie, M., Mohagheghi, M., Mousavi-Jarrahi, A., Malekezadeh, R., Parkin, D. (2005). Cancer occurrence in Iran in 2002, an international perspective. *Asian Pacific Journal of Cancer Prevention*, 6:359.

Salvador, M. J., Zucchi, T. D., Schinor, E. C., Dias, D. A., Zucchi, O. L. A. D., Poli, P., & Zucchi, T. M. A. D. (2008). Genotoxic potentials of natural products detected by a short-term test using diploid strains of *Aspergillus nidulans*. *The Open Mycology Journal*, 2(1), 48-54.

Schinor, E. C., Salvador, M. J., Ito, I. Y., De Albuquerque, S., & Dias, D. A. (2004). Trypanocidal and antimicrobial activities of *Moquinia kingii*. *Phytomedicine*, 11(2-3), 224-229.

Seca, A. M., & Pinto, D. C. (2018). Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. *International Journal of Molecular Sciences*, 19(1), 263.

Shakeri, A., Amini, E., Asili, J., Masullo, M., Piacente, S., & Iranshahi, M. (2018). Screening of several biological activities induced by different sesquiterpene lactones isolated from *Centaurea behen* L. and *Rhaponticum repens* (L.) Hidalgo. *Natural Product Research*, 32(12), 1436-1440.

Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. *CA: a Cancer Journal for Clinicians*, 65(1), 5-29.

Tanaka, Y. T., Tanaka, K., Kojima, H., Hamada, T., Masutani, T., Tsuboi, M., & Akao, Y. (2013). Cynaropicrin from *Cynara scolymus* L. suppresses photoaging of skin by inhibiting the transcription activity of nuclear factor-kappa B. *Bioorganic & Medicinal Chemistry Letters*, 23(2), 518-523.

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians*, 65(2), 87-108.

Tran, G. D., Sun, X. D., Abnet, C. C., Fan, J. H., Dawsey, S. M., Dong, Z. W., ... & Taylor, P. R. (2005). Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. *International Journal of Cancer*, 113(3), 456-463.

Wang, H., Deng, F., Liu, Q., & Ma, Y. (2017). Prognostic significance of lymph node metastasis in esophageal squamous cell carcinoma. *Pathology-Research and Practice*, 213(7), 842-847.

Wang, J., Wu, M., Zheng, D., Zhang, H., Lv, Y., Zhang, L., ... & Xu, H. X. (2020). Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways. *Acta Pharmacologica Sinica*, 41(1), 82-92.

Weber, C., and Noels, H. (2011). Atherosclerosis: current pathogenesis and therapeutic options. *Nature Medicine*. 17: 1410–1422.

- Wild-Bode, C., Weller, M., Rimner, A., Dichgans, J., Wick, W. (2001). Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. *Cancer Research*, 61: 2744-50.
- Wong, M. C., Hamilton, W., Whiteman, D. C., Jiang, J. Y., Qiao, Y., Fung, F. D., ... & Yu, J. (2018). Global incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. *Scientific Reports*, 8(1), 1-13.
- Xavier-ravi, B., vigila Antony-varuvel, G., Thangaraj, P., Doulatabad, M. R., & Rajan, K. (2019). Antioxidant, anti-inflammatory activities and HPLC quantification of flavonoids in *Pteris tripartita* Sw. a critically endangered medicinal fern from India. *Biocatalysis and Agricultural Biotechnology*, 21, 101304.
- Yadava, R. N., & Chakravarti, N. (2006). Novel Bioactive Triterpenoid saponin from *Centanurea behen* L. *Journal-Institution of Chemists (India)*, 78(5), 135.
- Yamada, K., Ishii, Y., Takeda, T., Kuroki, H., Mitoma, C., Uchi, H., ... & Yamada, H. (2015). Effect of cynaropicrin on 2, 3, 4, 7, 8-pentachlorodibenzofuran-induced wasting syndrome and oxidative stress. *Fukuoka igakuzasshi= Hukuokaactamedica*, 106(5), 169-175.
- Yang, G., Li, X., Wang, L., Li, J., Song, X., Chen, J., ...& Zhou, X. (2012). Traditional Chinese medicine in cancer care: a review of case series published in the Chinese literature. *Evidence-based Complementary and Alternative Medicine*, 31, 751046-751054.
- Yang, M. C., Choi, S. U., Choi, W. S., Kim, S. Y., & Lee, K. R. (2008). Guaiane sesquiterpene lactones and amino acid-sesquiterpene lactone conjugates from the aerial parts of *Saussurea pulchella*. *Journal of Natural Products*, 71(4), 678-683.
- Zhang, H. Z., Jin, G. F., & Shen, H. B. (2012). Epidemiologic differences in esophageal cancer between Asian and Western populations. *Chinese Journal of Cancer*, 31(6), 281.
- Zhang, J., Huang, F., Gong, T., & Liu, Z. (2020). SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4. *Cancer Letters*, 469, 390-398.
- Zhang, L., & Hu, C. M. J. (2012). Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. *Biochemical Pharmacology*, 83(8), 1104-1111.
- Zhang, S., Won, Y. K., Ong, C. N. & Shen, H. M. (2005). Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. *Current Medicinal Chemistry-Anti-Cancer Agents*, 5(3): 239-249.
- Zimmermann, S., Kaiser, M., Brun, R., Hamburger, M., & Adams, M. (2012). Cynaropicrin: the first plant natural product with *in vivo* activity against *Trypanosoma brucei*. *Planta Medica*, 78(06), 553-556.
- Zong, Y., Yu, M., Huang, L., Chang, Y., Wang, Y., & Che, C. T. (1994). Studies of Tibetan Medicinal Plants II. Antitumour activity of *Saussureae ophygmaea*. *International Journal of Pharmacognosy*, 32(3), 284-29.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [A.pdf](#)
- [C.pdf](#)
- [D.pdf](#)
- [Graph1.pzfx](#)
- [Graph2.pzfx](#)
- [Graph3.pzfx](#)
- [Graph4.pzfx](#)
- [Image.pdf](#)
- [S1.pdf](#)
- [S2.pdf](#)
- [S3.pdf](#)
- [S4.pdf](#)
- [S5.pdf](#)
- [S6.pdf](#)
- [comparison.pzfx](#)